Titanium surfaces immobilized with the major antimicrobial fragment FK-16 of human cathelicidin LL-37 are potent against multiple antibiotic-resistant bacteria

Mishra, Biswajit; Wang, Guangshun

doi:10.1080/08927014.2017.1332186

Cited by 51 publications

(50 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, FK16 has been shown to exhibit strong bactericidal activity against ESKAPE organisms ( Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumanii , Pseudomonas aeruginosa , and Enterobacter spp.) (Mishra and Wang, 2017). GF17, a N-glycinated variant of FK16, has also been shown to exhibit anti-cancer (Ren et al, 2013), anti-bacterial (Wang et al, 2012; Kiattiburut et al, 2018) and anti-viral activities (He et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa

et al. 2019

View full text Add to dashboard Cite

Pseudomonas aeruginosa (PA) is the leading cause of corneal blindness worldwide. A constant increase in multi-drug resistant PA strains have heightened the challenge of effectively managing corneal infections with conventional antibiotics. Antimicrobial peptides are promising antibiotic analogs with a unique mode of action. Cathelicidin-derived shorter peptides (FK13 and FK16) have previously been shown to kill a range of pathogens in both in vitro and in vivo systems. Here, our aim was to exploit the potential of FK13 or FK16 to enhance the anti-Pseudomonas activity of vancomycin, which normally has low clinical efficacy against PA. Our results have demonstrated that FK16 is more potent than FK13 against different PA strains including a clinical isolate from a patient’s ocular surface. FK16 was shown to enhance the membrane permeability of PAO1 at sub-inhibitory concentrations. Moreover, FK16 at lower concentrations was shown to increase the antibacterial susceptibility of vancomycin against PA strains up to eightfold. The bactericidal synergism between FK16 and vancomycin was shown to be stable in the presence of physiological tear salt concentration and did not cause toxic effects on the human corneal epithelial cells and human red blood cells. Our results have revealed that sub-inhibitory concentration of FK16 could augment the antimicrobial effects of vancomycin against PA. It is anticipated that the future exploitation of the peptide design approach may enhance the effectiveness of FK16 and its application as an adjuvant to antibiotic therapy for the treatment of multi-drug resistant infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It should be noticed that pexiganan was found to be effective in combinatory approach (low bacterial count) and also increased NK cytotoxic activity over the levels of infected and colistin-treated animals. LL-37 is the third most active peptide assessed in that study and, at the same time, the most extensively studied one against A. baumannii [ 41 – 44 ]. In the research conducted by Feng et al, antibacterial and antibiofilm activities of LL-37 and its fragments (KS-30, KR-20, KR-12) against clinical strains were determined [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial Activity of Selected Antimicrobial Peptides Against Planktonic Culture and Biofilm of Acinetobacter baumannii

Jaśkiewicz

Neubauer

Kazor

et al. 2018

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Acinetobacter baumannii is one of the most challenging pathogens, on account of its predisposition to develop resistance leading to severe, difficult-to-treat infections. As these bacteria are more usually isolated from nosocomial infections, the new therapeutic options are demanded. Antimicrobial peptides (AMPs) are compounds likely to find application in the treatment of A. baumannii. These compounds exhibit a wide spectrum of antimicrobial activity and were found to be effective against biofilm. In this study, eight AMPs, namely aurein 1.2, CAMEL, citropin 1.1., LL-37, omiganan, r-omiganan, pexiganan, and temporin A, were tested for their antimicrobial activity. A reference strain of A. baumannii ATCC 19606 was used. Antimicrobial assays included determination of the minimum inhibitory concentration and the minimum biofilm eradication concentration. Considering the fact that the majority of A. baumannii infections are associated with mechanical ventilation and the use of indwelling devices, the activity against biofilm was assessed on both a polystyrene surface and tracheal tube fragments. In addition, cytotoxicity (HaCaT) was determined and in vitro selectivity index was calculated.

show abstract

“… [ 238 ] Indolicidin Gold nanoparticles Prevent Candida albicans to form biofilms and impairs preformed mature biofilms [ 239 ] GL13K TiO 2 nanotubes Kill both F. nucleatum and P. gingivalis [ 240 ] FK-16 Titanium surface Anti-adhesion and biofilm inhibition capabilities against both S. aureus and E. coli . [ 241 ] OP-145 Polymer-Lipid Encapsulation MatriX Effective in killing S. aureus and inhibiting biofilm [ 242 ] KYE28 Poly(ethyl acrylate- co -methacrylic acid) microgels Anti-inflammatory effects on human monocytes Potent antifouling properties [ 243 ] …”

Section: Amps and Other Health Care Applicationsmentioning

confidence: 99%

Antimicrobial peptides – Advances in development of therapeutic applications

2020

View full text Add to dashboard Cite

The severe infection is becoming a significant health problem which threaten the lives of patients and the safety and economy of society. In the way of finding new strategy, antimicrobial peptides (AMPs) - an important part of host defense family, emerged with tremendous potential. Up to date, huge numbers of AMPs has been investigated from both natural and synthetic sources showing not only the ability to kill microbial pathogens but also propose other benefits such as wound healing, anti-tumor, immune modulation. In this review, we describe the involvements of AMPs in biological systems and discuss the opportunity in developing AMPs for clinical applications. In the detail, their properties in antibacterial activity is followed by their application in some infection diseases and cancer. The key discussions are the approaches to improve biological activities of AMPs either by modifying chemical structure or incorporating into delivery systems. The new applications and perspectives for the future of AMPs would open the new era of their development.

show abstract

Titanium surfaces immobilized with the major antimicrobial fragment FK-16 of human cathelicidin LL-37 are potent against multiple antibiotic-resistant bacteria

Cited by 51 publications

References 41 publications

Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa

Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa

Antimicrobial Activity of Selected Antimicrobial Peptides Against Planktonic Culture and Biofilm of Acinetobacter baumannii

Antimicrobial peptides – Advances in development of therapeutic applications

Contact Info

Product

Resources

About